The Group's principal activity is developing, manufacturing and marketing a range of generic and in-licensed pharmaceutical products in solid, semi-solid, liquid and injectable final dosages. It develops, manufactures and markets branded and unbranded generic, as well as in-licensed products in both oral and injectable dosage forms. The Group operates in three segments: Branded Pharmaceuticals, Generic Pharmaceuticals and Injectable Pharmaceuticals. Branded Pharmaceuticals segment develops, manufactures and markets 241 solid, semi-solid and liquid branded pharmaceutical products in 460 dosage strengths and forms, including 33 products under-license from the originator. Injectable Pharmaceuticals segment develops, manufactures and markets 81 injectable products in 202 dosage strengths. Generic Pharmaceuticals develops, manufactures and markets 47 non-branded generic pharmaceutical products in 105 dosage strengths and forms.
Alacra Alerts:
Receive alerts on the latest reports on Hikma Pharmaceuticals Plc
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
